Drug intelligence / Profile preview

D-GPEi

Development stage: Phase 1
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

D-GPEi is a DNA vaccine candidate developed for HIV/AIDS. It was evaluated in a clinical trial (NCT01881581) to assess its safety and immunogenicity in healthy adults. The vaccine is administered via intramuscular injection at varying doses (0.5 mg, 2 mg, or 4 mg). As a DNA vaccine, D-GPEi works by introducing genetic material encoding HIV antigens into the body, prompting host cells to produce these antigens and thereby stimulating an immune response against HIV[3]. The specific antigenic components encoded by D-GPEi are not detailed in the available sources.

Targets

Env (HIV-1 envelope glycoprotein)

Beyond the preview

Go deeper on D-GPEi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-GPEi.

Explore the full profile